Clinical Trial Update: Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial of Glivec (imatinib) for unresectable or metastatic malignant gastrointestinal stromal tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Glivec (imatinib)

Snippet

Sponsor: Central European Cooperative Oncology Group | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: COMPLETED